Background Long-term hormone therapy alone is usually standard care for metastatic

Background Long-term hormone therapy alone is usually standard care for metastatic or high-risk non-metastatic prostate malignancy. across seven stratification factors. Patients randomly allocated to arm D received celecoxib 400 mg twice daily given orally until 1 year or disease progression (including prostate-specific antigen [PSA] failure). The intermediate end result was failure-free survival (FFS) in three… Continue reading Background Long-term hormone therapy alone is usually standard care for metastatic